You'll find the Nastiuk Lab’s research published in JCI Insight, Nature Communications, Cancers, and more.
- Zhang R, et al. Rate of castration-induced prostate stroma regression is reduced in a mouse model of benign prostatic hyperplasia. Am J Clin Exp Urol. 2023;11(1):12-26.
- Krolewski JJ, et al. TNF Signaling Is Required for Castration-Induced Vascular Damage Preceding Prostate Cancer Regression. Cancers (Basel). 2022 Dec 7;14(24). doi: 10.3390/cancers14246020.
- Omole EB, et al. Combined BRCA2 and MAGEC3 Expression Predict Outcome in Advanced Ovarian Cancers. Cancers (Basel). 2022 Sep 28;14(19). doi: 10.3390/cancers14194724.
- Vickman RE, et al. TNF is a potential therapeutic target to suppress prostatic inflammation and hyperplasia in autoimmune disease. Nat Commun. 2022 Apr 19;13(1):2133. doi: 10.1038/s41467-022-29719-1.
- Li F, et al. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma. J Exp Clin Cancer Res. 2021 Aug 12;40(1):254. doi: 10.1186/s13046-021-02026-1.
- Pan C, et al. Prostate tumor-derived GDF11 accelerates androgen deprivation therapy-induced sarcopenia. JCI Insight. 2020 Mar 26;5(6). doi: 10.1172/jci.insight.127018.
- Schmitthenner HF, et al. Modular Synthesis of DOTA-Metal-Based PSMA-Targeted Imaging Agents for MRI and PET of Prostate Cancer. Chemistry. 2019 Nov 4;25(61):13848-13854. doi: 10.1002/chem.201903390.
- Lerman I, et al. Epigenetic Suppression of SERPINB1 Promotes Inflammation-Mediated Prostate Cancer Progression. Mol Cancer Res. 2019 Apr;17(4):845-859. doi: 10.1158/1541-7786.MCR-18-0638.
Connect with the Nastiuk Lab
Department of Cancer Genetics & Genomics
Roswell Park Comprehensive Cancer Center
Elm and Carlton Streets
Buffalo, NY 14263